Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics: a tool for individualizing antineoplastic therapy.

F Innocenti1, L Iyer, M J Ratain

  • 1Department of Medicine, The University of Chicago, Illinois 60637, USA.

Clinical Pharmacokinetics
|December 7, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

ESMO open·2025
Same author

Evaluation of outcomes, costs, and feasibility of home-based geriatric rehabilitation after inpatient rehabilitation: study protocol of the "Better@Home" multicentre prospective cohort study with historical control group.

BMC geriatrics·2025
Same author

Socio-Economic Determinants and Regional Prevalence of Disorders of Gut-Brain Interaction in the Netherlands: Results From the Rome Foundation Global Epidemiology Study.

Neurogastroenterology and motility·2025
Same author

Value of PGT-A when only one or two blastocysts are obtained: propensity-score matching and cost-effectiveness study.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same author

Role of thyroid stimulating hormone in the maintenance and functioning of the human corpus luteum.

Journal of endocrinological investigation·2024
Same author

Editorial: Cardiovascular involvement during sepsis: therapeutic and prognostic consequences.

Frontiers in cardiovascular medicine·2023

Pharmacogenetics significantly impacts cancer chemotherapy outcomes. Genetic variations influence drug metabolism, enabling personalized dosing for mercaptopurine and irinotecan to reduce toxicity and improve patient results.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Genetic variations in enzyme metabolism critically affect cancer drug efficacy and toxicity.
  • Understanding these variations is key to personalizing chemotherapy regimens.
  • Pharmacogenetics offers a framework for optimizing cancer treatment based on individual genetic profiles.

Purpose of the Study:

  • To review the clinical significance of pharmacogenetics in cancer chemotherapy.
  • To highlight drugs where genetic differences in metabolism impact patient outcomes.
  • To discuss strategies for dose individualization based on genetic and phenotypic data.

Main Methods:

  • Review of existing literature on pharmacogenetics in cancer chemotherapy.
  • Analysis of specific drug examples: mercaptopurine, fluorouracil, irinotecan, and amonafide.

Related Experiment Videos

  • Discussion of diagnostic approaches including phenotyping and genotyping.

    • Main Results:

    • Genetic defects in thiopurine S-methyltransferase (TPMT) cause mercaptopurine intolerance in ~10% of pediatric leukemia patients, manageable with TPMT phenotyping/genotyping.
    • Reduced fluorouracil (5-FU) catabolism increases toxicity risk; dihydropyrimidine dehydrogenase (DPD) activity measurement is not fully predictive.
    • UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter variants are linked to reduced irinotecan (SN-38) inactivation and increased toxicity, identifiable via genotyping.

    Conclusions:

    • Pharmacogenetic testing is crucial for optimizing cancer chemotherapy, particularly for drugs like mercaptopurine and irinotecan.
    • Personalized dosing strategies based on genetic profiles can mitigate severe drug toxicity.
    • Further research is needed to clarify the role of DPD gene variants in fluorouracil toxicity.